Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jan 6, 2011 (rev. 1)

Premium

BioMérieux this week announced the appointment of James Whelan as executive vice president of commercial services.

In this newly created role, Whelan will be responsible for reinforcing BioMérieux's global service offering, which will include expanded customer lab audits, laboratory accreditation support, and comprehensive scientific training programs, BioMérieux said.

Prior to joining BioMérieux, Whelan was president of clinical diagnostics at Magellan Biosciences. From 2003 to 2007, he worked at Laboratory Corporation of America; and prior to that he worked at Fisher Scientific (now Thermo Fisher), where he held sales and management positions for 21 years.


Danish molecular diagnostics firm FluimediX said this week that Ove Öhman has joined the company's board as a non-executive director.

Öhman helped found Åmic, a Swedish diagnostic company for which he also served as chairman, CEO, and vice president of R&D for more than 10 years prior to its acquisition by Johnson & Johnson in 2008. Öhman has also held positions with Biacore, Pharmacia, and Toolex Alpha. He is currently a co-founder and CEO of Fiomi Diagnostics.

FluimediX is developing the NanoCycler point-of-care diagnostic platform for identifying SNPs for diagnosing and treating diseases.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.